Tacton Acquires Variantum and Serenytics to Deliver the Most Complete End-to-End Platform for Complex Manufacturers
7.10.2025 08:00:00 CEST | Business Wire | Press Release
Tacton, the global leader in CPQ Buyer Engagement solutions for complex manufacturers, announced today the acquisition of Variantum, a Finnish software company specializing in Configuration Lifecycle Management (CLM), Configurable Order Fulfillment (COF), and Configured Installed Base (CIB). The move expands Tacton’s platform beyond Configure, Price, Quote (CPQ) into engineering, order fulfillment, and service, creating the most complete end-to-end platform for manufacturers of configured products.
Tacton has also acquired Serenytics, a French-based analytics provider. With Serenytics embedded, the platform now delivers near real-time enterprise insights & analytics into buyer behavior, product performance and lifecycle profitability giving manufactures a single source of truth to make every decision accurate, profitable and data-driven.
Closing the Gaps in Manufacturing
Manufacturers of complex, customized equipment have long been held back by disconnected processes and siloed data. Sales, engineering, and production often operate in separate systems with conflicting information that results in quoting errors, costly engineering handovers, margin erosion, and late deliveries.
“With Variantum, we are solving one of manufacturing’s most critical challenges: connecting what is sold with what is engineered, built, and delivered,” said Klaus Andersen, CEO of Tacton. “For the first time, manufacturers can unify the entire lifecycle within one platform, ensuring accuracy, speed, and profitability from start to finish.”
Connecting the Lifecycle from Design to Delivery
Founded in 2005 in Espoo, Finland, Variantum brings deep expertise in lifecycle-wide configuration. Its products help manufacturers:
- Ensure lifecycle integrity with a single source of truth for configurability across engineering, sales, and production with Configuration Lifecycle Management (CLM).
- Deliver profitably with automated, order-specific manufacturing BOMs, optimized routing, and traceable change management with Configured Order Fulfillment (COF).
- Grow beyond the initial sale with Configured Installed Base management that enables upgrades, service, and compliance across the product lifecycle (CIB).
“Variantum was built to connect engineering, sales, and production into one seamless flow,” said Hanna Kemppainen, CEO of Variantum and now SVP Executive Projects. “By joining Tacton, we can now bring that vision to global scale. Together, we are enabling manufacturers to sell it right, build it right, and deliver it right every time.”
Seamless Intelligence Across the Lifecycle
While Variantum brings lifecycle and fulfillment, Serenytics ensures every stage is optimized by data. The acquisition embeds advanced analytics directly into the platform, giving manufacturers near real-time visibility into buyer behavior, product performance, and lifecycle profitability, without reliance on external BI tools.
“Manufacturers don’t just need more data. They need the right insights at the right time,” added Andersen. “With Serenytics, Tacton provides a single source of truth across the lifecycle, helping teams make faster, smarter, and more profitable decisions.”
“Serenytics was founded to put data directly in the hands of decision-makers,” said Adrien Auclair, founder of Serenytics and now Software Architect at Tacton. “With Tacton, we’re embedding that vision inside one of the most powerful Buyer Engagement Platforms in complex manufacturing.”
Creating the Buyer-Centric Smart Factory
The combined capabilities advance Tacton’s vision of the Buyer-Centric Smart Factory. Recognized as the global leader in CPQ for complex manufacturing, Tacton has already transformed how manufacturers configure complex products and increase revenue. With the addition of Variantum and Serenytics, Tacton can now extend across the entire lifecycle. Manufacturers can now:
- Gain Control of Product Configurability: Create a single source of truth for configurability across the lifecycle, connected to revisions of the product architecture and bill of materials, with full transparency in Sales and Order Fulfillment.
- Sell Faster: Empower sales teams to deliver accurate, compelling proposals without engineering bottlenecks. Bring solutions to life with advanced visualization that allows buyers to experience products virtually in their own environment.
- Deliver a Better Buyer Experience: Put customer needs first by creating a simple, intuitive, and engaging buying process that strengthens trust and loyalty.
- Build Profitably: Ensure every order is manufacturable and margin-protected through a seamless flow of validated configuration data.
- Deliver Beyond the Sale: Unlock service, upgrades, and lifecycle insights for stronger customer relationships.
- Decide Smarter: Use embedded analytics to turn lifecycle data into actions and accelerate growth.
Under the leadership of newly appointed CEO Klaus Andersen, Tacton is executing a clear strategy to expand beyond CPQ and lead the industry in not only buyer engagement but also in smart factory. Andersen is accelerating innovation by uniting sales, engineering, order fulfillment, and aftermarket into one platform. These strategic investments position Tacton as the only provider delivering an end-to-end Buyer Engagement Platform that connects every stage of the lifecycle and powers it with real-time insights.
“These acquisitions mark a bold step forward,” concluded Andersen. “Our customers have told us they need more than CPQ. They need a connected flow that ensures what is sold can be built, delivered, and serviced profitably. The Buyer-Centric Smart Factory is our answer — a complete platform where every step is aligned, every margin protected, and every outcome powered by data.”
Learn more about how Tacton is redefining buyer engagement with Variantum and Serenytics.
About Variantum
Founded in 2005 and headquartered in Espoo, Finland, Variantum specializes in configuration solutions for complex manufacturing. Its product portfolio includes Configuration Lifecycle Management (CLM), Configurable Order Fulfillment (COF), and Configured Installed Base Management (CIB). Variantum has served global manufacturers such as KONE, Abloy, and Chiller, helping them connect engineering, sales, and production processes into one seamless flow.
About Serenytics
Serenytics is a SaaS data visualization platform that enables advanced dashboard creation in just a few clicks, with no need for developers. It supports connecting data via CSV, API, SQL, or data warehouses, handling small to very large datasets. Founded in France in 2015, Serenytics makes complex data usable and shareable across teams and systems.
About Tacton
Tacton is a leading SaaS company, redefining CPQ buyer engagement for manufacturers of complex configurable products. By streamlining the buyer journey, Tacton empowers manufacturers to accelerate go-to-market strategies, increase sales, and build brand loyalty. Trusted since 1998 by global leaders such as ABB, Daimler, MAN, Scania, Siemens, Xylem, and Yaskawa, Tacton continues to drive innovation in manufacturing. The company is co-headquartered in Chicago and Stockholm, with regional offices in Karlsruhe, Warsaw, Helsinki, Paris and Tokyo. Learn more at tacton.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251006237381/en/
Contacts
Marketbridge
Gail Scibelli
gscibelli@marketbridge.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom